Datavant Blog

Tiffani Snider — Tiffani is a retired Marine Sergant and mental health professional specializing in Veteran trauma, LBGTQ+ equality and bridging the gap in Veteran Affair services in underserved population. Tiffani works in partnerships with Veteran owned businesses across the US to raise awareness around Veteran suicide prevention tactics.

Count Me In aims to put the power of health data back in the hands of the people. The app allows people to choose what data they have access to, who can use that data, and how much they should be reimbursed for having that data. Count Me In is positioned in contrast to the current state of healthcare, where data can be a form currency in the healthcare market.

My journey from “accidental” People person to supporting the needs of a highly diverse workforce of 9,000 employees changing the face of…

Discover how healthcare data linking is being conducted with small populations while maintaining patient privacy.

In Part 1 of this article, we discussed the evolving scientific landscape of disclosure risk in genetics data. In Part 2, we explore the legislative outcomes of this development. In particular, we will analyze the requirements of the HIPAA Omnibus Rule (2013) and propose a framework for how privacy experts should apply these in practice.

Leon Ho joined Datavant in 2019 and has been twice promoted from Individual Contributor to Engineering Manager. Below, Leon reflects on the constantly evolving nature of the Engineering team at Datavant, and how this dynamism has directly supported his goals for personal and professional growth.

Learn how advances in genomics impacts genomic data privacy and how studies can adjust to meet new requirements.

Over the last three years, the proliferation of real-world data at scale has dramatically changed how researchers are thinking about study design, operations, and execution – and the role digital patient data can play. We believe that over the next five years, tokenized clinical trials will be critical to reducing study costs and a force multiplier for accelerating therapeutic innovations for patients. Read this blog post to learn more about about vision and investment in trial tokenization.

In our Data & Analytics Thought Leader Series, Datavant’s Head of Data Strategy, Su Huang, interviews leaders who are advancing data-driven use cases at their organization. This interview is with Sid Jain, Head, Global Development, Data Science at Janssen Research & Development, LLC. At Janssen, Sid and his team are focused on using data science tools and technologies, like artificial intelligence (AI) and machine learning (ML), to accelerate clinical development, with a commitment to not only making drug development faster, better and more efficient – but also making science possible that was not possible before.